Source: GlobalNewswire

Press Release: Macdougall Biomedical Communications : MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 08, 2019 (GLOBE NEWSWIRE) --MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March:

Read full article »
Macdougall Biomedical Communications's Competitors | Macdougall Biomedical Communications's News | Macdougall Biomedical Communications's Financials
Stay up-to-date with the latest news on MacDougall
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Douglas MacDougall's photo - Managing Partner of MacDougall

Managing Partner

Douglas MacDougall

CEO Approval Rating

88/100

Read more
Stay up-to-date with the latest news on MacDougall